logo-loader
viewAdvanced Oncotherapy PLC

Advanced Oncotherapy on track to treat first cancer patient by end of 2020

Building work at the Harley Street facility is progressing to schedule, and bosses are confident the ground-breaking LIGHT proton beam therapy system will treat its first patient towards the end of next year

harley street
Proton beam therapy can target cancers more precisely

Advanced Oncotherapy PLC (LON:AVO) remains on track to treat the first cancer patient at its Harley Street facility by the end of 2020.

The AIM company is developing a state-of-the-art, affordable proton beam therapy system called light, which it is currently installing in a town house in central London.

Building work is progressing to schedule, with much of the system due to be in place by the end of this year.

READ: AVO announces positive results from comparative study

As AVO moves nearer to treating the first patient, it has started to gear up its commercial infrastructure with the recent appointment of an experienced chief commercial officer.

Moataz Karmalawy is a “veteran in the commercialisation of PBT technology”, according to research house Hardman & Co, given his previous jobs at Varian and Philips Medical.

“I am very pleased with the progress that we are making to develop a more affordable proton-based radiotherapy system which will ultimately facilitate the wider use of radiation with protons for treating radio-sensitive tumours,” said chief executive Nicolas Serandour.

“Whilst we appreciate that we still have challenges ahead, the achievements we have made further strengthen our dedication and commitment to deliver our game-changing technology to a substantial international market.”

2018 results

For the year ended 31 December 2018, Advanced Onco recorded a loss of £20.2mln (2017: £14.7mln).

At the end of the period, it had £1.0mln of cash in the bank, although it has since secured financing of £12.3ml, including a £10mln debt facility from Credit Suisse.

Shares were flat at 45p on Friday morning.

Quick facts: Advanced Oncotherapy PLC

Price: 38.5 GBX

LSE:AVO
Market: LSE
Market Cap: £93.88 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Advanced Oncotherapy PLC named herein, including the promotion by the Company of Advanced Oncotherapy PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: VR Education's ENGAGE platform to be included in new 5G VR...

Headlines from the Proactive UK newsroom. VR Education’s (LON:VRE) Engage platform has been chosen as an embedded title in a new 5G virtual reality headset being developed by a consortium of Deutsche Telekom, Qualcomm and XRSPACE. The new headset is due to launch in...

5 days, 12 hours ago

RNS

Holding(s) in Company

6 days, 3 hours ago

Total Voting Rights

1 week, 3 days ago

Holding(s) in Company

1 week, 4 days ago

Total Voting Rights

on 6/11/19

Change of Broker

on 10/10/19

Total Voting Rights

on 30/9/19

2 min read